西达本胺联合吗替麦考酚酯抑制继发性急性髓系白血病细胞增殖

蔡铎; 梁思敏; 周巧; 王利

doi:10.16016/j.2097-0927.202201220

您当前的位置：

首页 >

文章列表页 >

西达本胺联合吗替麦考酚酯抑制继发性急性髓系白血病细胞增殖

基础医学 | 更新时间：2026-01-09

- 西达本胺联合吗替麦考酚酯抑制继发性急性髓系白血病细胞增殖
- Chidamide combined with mycophenolate mofetil suppress proliferation of secondary acute myeloid leukemia cells
- 陆军军医大学学报 2022年44卷第13期页码：1338-1348
- 作者机构：
  
  1.400016 重庆，重庆医科大学附属第一医院：血液内科
  2.400016 重庆，重庆医科大学附属第一医院：重大代谢性疾病转化医学重点实验室
- 作者简介：
  
  [王利，E-mail：liwangls@yahoo.com WANG Li, E-mail: liwangls@yahoo.com
- 基金信息：
  
  重庆市科卫联合医学科研项目重点项目(2018ZDXM001)
- DOI：10.16016/j.2097-0927.202201220
  中图分类号： R733.7;R965;R979.1
- 收稿：2022-01-23，
  
  修回：2022-03-05，
  
  纸质出版：2022-07-15
- 稿件说明：
移动端阅览
蔡铎, 梁思敏, 周巧, 等. 西达本胺联合吗替麦考酚酯抑制继发性急性髓系白血病细胞增殖[J]. 陆军军医大学学报, 2022,44(13):1338-1348.

Duo CAI, Simin LIANG, Qiao ZHOU, et al. Chidamide combined with mycophenolate mofetil suppress proliferation of secondary acute myeloid leukemia cells[J]. Journal of Army Medical University, 2022, 44(13): 1338-1348.
蔡铎, 梁思敏, 周巧, 等. 西达本胺联合吗替麦考酚酯抑制继发性急性髓系白血病细胞增殖[J]. 陆军军医大学学报, 2022,44(13):1338-1348. DOI： 10.16016/j.2097-0927.202201220.

Duo CAI, Simin LIANG, Qiao ZHOU, et al. Chidamide combined with mycophenolate mofetil suppress proliferation of secondary acute myeloid leukemia cells[J]. Journal of Army Medical University, 2022, 44(13): 1338-1348. DOI： 10.16016/j.2097-0927.202201220.

摘要

目的

探讨西达本胺(chidamide，CDM)和吗替麦考酚酯(mycophenolate mofetil，MMF)联合应用对继发性急性髓系白血病细胞增殖的影响。

方法

慢性髓系白血病急变期细胞株K562及MDS转白细胞株SKM-1，分别按照不同浓度的CDM单药组(0.25、0.5、1、2、4 μmol/L)，MMF单药组(0.5、1、2、4、8 μmol/L)及联合用药组(CDM∶MMF=1∶2)干预24、48、72 h后，CCK-8实验检测细胞增殖抑制率。基于最佳联合干预浓度干预72 h后，流式细胞学检测细胞周期及凋亡率的变化，并通过网络药理学探讨其作用机制。

结果

CCK-8结果显示，联合组(1 μmol/L CDM+2 μmol/L MMF)在K562和SKM-1细胞中的联合指数分别为0.389 44和0.630 98。与CDM及MMF单药组比较，联合用药能显著提高对K562和SKM-1细胞增殖抑制率(

0.01)，并促进K562细胞凋亡率增高(

0.05)。相较单药MMF组，联合组显著诱导K562、SKM-1细胞G

期阻滞，但较CDM单药无统计学差异。其后网络药理学构建出66个节点、222条边的药物-疾病靶点PPI网络，并根据拓扑学筛选出CDK1、CDK2、CDK4、CDK6、CDK9、SYK、BTK、KDR、PIK3CB等9个核心靶点，富集分析主要涉及蛋白质磷酸化、细胞增殖、凋亡调控等多种生物进程，及PI3K-AKT、FOXO等信号通路。

结论

CDM联合MMF可显著抑制继发性急性髓系白血病细胞生长。

Abstract

Objective

To investigate the effects of combined application of chidamide (CDM) and mycophenolate mofetil (MMF) on the proliferation of secondary acute myeloid leukemia (sAML) cells.

Methods

Chronic myeloid leukemia blast-phase cell line K562 and myelodysplastic syndromes (MDS)-transformed leukocyte line SKM-1 were employed in the study. The cells were divided into groups according to different concentrations of intervention drugs: CDM alone groups (0.25

0.5

2 and 4 μmol/L)

MMF alone groups (0.5

4 and 8 μmol/L) and combined drug groups (CDM∶MMF=1∶2)

respectively. The inhibitory rate of cell proliferation was detected by CCK-8 assay after treatment for 24

48 and 72 h

respectively. Moreover

the changes of cell cycle and apoptotic rate were determined by flow cytometry after 72 h of intervention under the optimal combined drug concentration

and its mechanism was analyzed by network pharmacology.

Results

CCK-8 assay showed that the combination index of the combined drug group (1 μmol/L CDM+2 μmol/L MMF) was 0.389 44 in K562 cells and 0.630 98 in SKM-1 cells. When compared with the CDM and MMF monotherapy groups

the combined treatment significantly enhanced the inhibitory effect on the proliferation of both K562 and SKM-1 cells (

0.01)

and increased the apoptotic rate of K562 cells (

0.05). As compared with the MMF alone group

the combination group remarkably arrested the cell cycle at the G

phase

though which had no statistical difference with CDM alone. Subsequently

a drug-disease target protein-protein interaction (PPI) network including 66 nodes and 222 edges was constructed through network pharmacology

and 9 core targets including CDK1

CDK2

CDK4

CDK6

CDK9

SYK

BTK

KDR

and PIK3CB were screened out according to topology. Enrichment analysis indicated that various biological processes such as protein phosphorylation

cell proliferation

and apoptosis regulation were mainly involved

as well as PI3K-AKT

FOXO and other signaling pathways.

Conclusion

CDM combined with MMF significantly inhibits the growth of sAML cells.

关键词

Keywords

references

JABBOUR E, KANTARJIAN H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring[J]. Am J Hematol, 2020, 95(6): 691-709. DOI: 10.1002/ajh.25792.

SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551.

NATIONAL CANCER INSTITUTE. SEER cancer statistics review(CSR) 1975-2016[EB/OL]. [2020-04-09]. https://seer.cancer.gov/csr/1975_2016/.

董悦昕. 继发性急性髓系白血病和粒细胞缺乏性发热的临床分析[D]. 上海: 上海交通大学, 2020.

DONG Y X. Clinical study of secondary acute myeloid leukemia and febrile neutropenia[D]. Shanghai: Shanghai Jiaotong University, 2020.

NCCN. NCCN clinical practice guidelines in oncology acute myeloid leukemia Version 3.2020[EB/OL]. [2020-12-21]. http://www.nccn.org.

WALTER R B, ESTEY E H. Management of older or unfit patients with acute myeloid leukemia[J]. Leukemia, 2015, 29(4): 770-775. DOI: 10.1038/leu.2014.216.

JAIN P, KANTARJIAN H M, GHORAB A, et al . Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients[J ] . Cancer, 2017, 123(22): 4391-4402. DOI: 10.1002/cncr.30864.

PAVIGLIANITI A, LABOPIN M, BLAISE D, et al . Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT[J ] . Bone Marrow Transplant, 2021, 56(5): 1077-1085. DOI: 10.1038/s41409-020-01155-z.

VILLARROEL M C, HIDALGO M, JIMENO A. Mycophenolate mofetil: an update[J]. Drugs Today (Barc), 2009, 45(7): 521-532. DOI: 10.1358/dot.2009.45.7.1384878.

JAYARAM H N, COONEY D A, GRUSCH M, et al . Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis[J ] . Curr Med Chem, 1999, 6(7): 561-574.

KOFUJI S, HIRAYAMA A, EBERHARDT A O, et al . IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma[J ] . Nat Cell Biol, 2019, 21(8): 1003-1014. DOI: 10.1038/s41556-019-0363-9.

KOEHL G E, WAGNER F, STOELTZING O, et al . Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo , possibly related to bioavailability[J ] . Transplantation, 2007, 83(5): 607-614. DOI: 10.1097/01.tp.0000253756.69243.65..

NAFFOUJE R, GROVER P, YU H Y, et al . Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story[J ] . Cancers, 2019, 11(9): 1346. DOI: 10.3390/cancers11091346.

TRESSLER R J, GARVIN L J, SLATE D L. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo [J ] . Int J Cancer, 1994, 57(4): 568-573. DOI: 10.1002/ijc.2910570421.

栗若兰, 郑智慧, 路新华, 等. 霉酚酸对人结肠癌SW620细胞凋亡的诱导作用及其机制[J]. 河北师范大学学报(自然科学版), 2013, 37(5): 519-523. DOI: 10.13763/j.cnki.jhebnu.nse.2013.05.010.

LI R L, ZHENG Z H, LU X H, et al . Induction effect of mycophenolic acid on apoptosis of human colon cancer cell line SW620 and its mechanism[J ] . J Hebei Norm Univ Nat Sci Ed, 2013, 37(5): 519-523. DOI: 10.13763/j.cnki.jhebnu.nse.2013.05.010.

TAKEBE N, CHENG X F, FANDY T E, et al . IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells[J ] . Mol Cancer Ther, 2006, 5(2): 457-466. DOI: 10.1158/1535-7163.MCT-05-0340.

ENGL T, MAKAREVIĆ J, RELJA B, et al . Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy[J ] . BMC Cancer, 2005, 5: 4. DOI: 10.1186/1471-2407-5-4.

INAI K, TSUTANI H, YAMAUCHI T, et al . Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil[J ] . Leuk Res, 2000, 24(9): 761-768. DOI: 10.1016/s0145-2126(00)00045-x.

XU W S, PARMIGIANI R B, MARKS P A. Histone deacetylase inhibitors: molecular mechanisms of action[J]. Oncogene, 2007, 26(37): 5541-5552. DOI: 10.1038/sj.onc.1210620.

SANAEI M, KAVOOSI F. Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers[J]. Adv Biomed Res, 2019, 8: 63. DOI: 10.4103/abr.abr_142_19.

LIANG S M, ZHOU X J, CAI D, et al . Chidamide inhibits cell proliferation via the PI3K/AKT pathway in K562 cells based on network pharmacology and experimental validation[J ] . Curr Pharm Des, 2021, 27(26): 2990-2998. DOI: 10.2174/1381612827666210701152250..

张黎琴. 西达本胺对K562/G01细胞增殖抑制、凋亡及Hedgehog信号通路相关机制的研究[D]. 太原: 山西医科大学, 2018.

ZHANG L Q. Study of the effects of chidamide on proliferation, apoptosis and related mechanism of hedgehog signaling in K562/G01 cells[D]. Taiyuan: Shanxi Medical University, 2018.

王世广, 司旭艳, 李晓婷, 等. 西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性[J]. 解剖学报, 2019, 50(6): 754-760. DOI: 10.16098/j.issn.0529-1356.2019.06.009.

WANG S G, SI X Y, LI X T, et al . Enhancing effect of chidamide on the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin[J ] . Acta Anat Sin, 2019, 50(6): 754-760. DOI: 10.16098/j.issn.0529-1356.2019.06.009.

XU F F, GUO H G, SHI M Y, et al . A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines[J ] . Am J Transl Res, 2019, 11(12): 7644-7655.

CHEN K, YANG Q Y, ZHA J, et al . Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia[J ] . Cell Death Dis, 2020, 11(9): 778. DOI: 10.1038/s41419-020-02972-2.

LI X, YAN X, GUO W J, et al . Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine[J ] . Biomed Pharmacother, 2017, 90: 699-704. DOI: 10.1016/j.biopha.2017.04.037.

HUANG H, YANG W B, DONG A S, et al . Chidamide enhances the cytotoxicity of cytarabine and sorafenib in acute myeloid leukemia cells by modulating H3K9me3 and autophagy levels[J ] . Front Oncol, 2019, 9: 1276. DOI: 10.3389/fonc.2019.01276.

刘洋. 雷公藤治疗口腔鳞状细胞癌的网络药理学分析和分子对接研究[D]. 太原: 山西医科大学, 2021.

LIU Y. Network pharmacology analysis and molecular docking study of Tripterygium wilfordii Hook. F. in the treatment of oral squamous cell carcinoma[D]. Taiyuan: Shanxi Medical University, 2021.

LIM S, KALDIS P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation[J]. Dev Camb Engl, 2013, 140(15): 3079-3093. DOI: 10.1242/dev.091744.

周俊, 单慧蓉, 王小龙, 等. CDK4/6对急性白血病细胞增殖及凋亡的影响[J]. 江苏医药, 2017, 43(17): 1209-1212. DOI: 10.19460/j.cnki.0253-3685.2017.17.001.

ZHOU J, SHAN H R, WANG X L, et al . Influence of CDK4/6 on proliferation and apoptosis of acute leukemia cells[J ] . Jiangsu Med J, 2017, 43(17): 1209-1212. DOI: 10.19460/j.cnki.0253-3685.2017.17.001.

舒可. CDK4抑制剂及FLT3抑制剂的设计、合成与生物活性评价[D]. 杭州: 浙江大学, 2019.

SHU K. Design, synthesis and bioactivity evaluation of CDK4 inhibitors and FLT3 inhibitors[D]. Hangzhou: Zhejiang University, 2019.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Z-藁本内酯通过抑制PI3K/AKT信号通路延缓视网膜色素变性：基于网络药理学与分子对接验证

槲皮素抑制铁死亡减轻肠缺血再灌注损伤

佛手柑内酯延缓骨关节炎软骨细胞衰老

基于网络药理学与分子对接和体外实验探讨青蒿治疗脓肿分枝杆菌感染的研究

基于网络药理学及分子对接方法研究黄芪治疗血管性痴呆的机制